Application Note

A Human HTS Platform For Assessing Gastrointestinal Toxicity (GIT) Risk In Early Development

Source: Altis Biosystems
intestine iStock-1138681666

GI tract represents the most common target organ of adverse drug reactions (35% of clinical AEs). Clinical safety failures are only predicted by nonclinical studies 25% of the time. Why?

  • Lack of predictable in vitro models
  • Rodents show low concordance (42%) with human clinical outcomes4
  • Non-human primates are more predictive, but limited by cost, throughput, and ethics (reserved for lead)4

There is a significant unmet need for human models of GI risk assessment that can be utilized for drug optimization in early development. We review a solution with high quality Human GI stem cell platform, diverse donor demographics (age, race, sex), and rigorous quality control of all cell lots.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online